Monitor for future filings regarding trial initiation, Health Canada approvals, and patient enrollment milestones. No near-term stock catalyst from this appointment alone.
Price Chart
Executive Summary
Optimi Health appointed Dr. Michael Blough as Chief Clinical Development Officer, a newly created role overseeing the company's planned Phase 2 psilocybin trial for major depressive disorder and Phase 3 MDMA trial for PTSD. Both trials are expected to begin enrolling patients next year. This is a routine executive appointment with no financial terms disclosed and no immediate catalyst for the stock.
Key Facts
- Dr. Michael Blough appointed as Chief Clinical Development Officer, a newly created position.
- He will oversee Optimi's planned Phase 2 psilocybin trial for major depressive disorder and Phase 3 MDMA trial for PTSD.
- Both trials expected to begin enrolling patients next year (2027).
- Dr. Blough has worked with Optimi on clinical trial applications since 2022.
- No financial terms, compensation, or material agreements disclosed.
Financial Impact
No financial impact disclosed; appointment is a personnel change with no associated costs or revenue figures.
Risk Factors
- Clinical trial timelines may slip; enrollment expected 'next year' but no firm dates provided.
- Regulatory risks from Health Canada and FDA for psychedelic drug approvals.
- No revenue or financial data disclosed; company remains pre-revenue on these pipeline programs.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006164 |
| Document: f6k_092226.htm | 0001171843-26-006164 |
| Document: 0001171843-26-006164-index-headers.html | 0001171843-26-006164 |
| Document: 0001171843-26-006164-index.html | 0001171843-26-006164 |
| Document: 0001171843-26-006164.txt | 0001171843-26-006164 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $3.36 | awaiting T+5 | — | $3.12 (−7.14%) |
Oct 20, 2026 6d ago | 6-K | $3.36 | awaiting T+5 | — | $3.12 (−7.14%) |
Oct 7, 2026 19d ago | 6-K | $4.04 $3.17 | ▼ −21.66% | ▼ −20.68% | $3.12 (−22.77%) |
Oct 5, 2026 21d ago | SC 13G/A | $4.13 $3.50 | ▼ −15.25% | ▼ −15.12% | $3.12 (−24.46%) |
Sep 29, 2026 27d ago | 6-K | $4.78 $4.13 | ▼ −13.60% | ▼ −15.55% | $3.12 (−34.73%) |
Sep 23, 2026 4w ago | 6-K | $4.96 $4.71 | ▼ −5.04% | ▼ −4.37% | $3.12 (−37.10%) |
Sep 22, 2026 4w ago | 6-K | $4.96 $4.78 | ▼ −3.63% | ▼ −2.44% | $3.12 (−37.10%) |
Sep 16, 2026 5w ago | 6-K | $4.90 $4.96 | ▲ +1.22% | ▼ −0.60% | $3.12 (−36.33%) |
Sep 10, 2026 6w ago | 6-K | $4.50 $4.96 | ▲ +10.22% | ▲ +10.72% | $3.12 (−30.67%) |
Aug 26, 2026 8w ago | 6-K | $4.89 $4.70 | ▲ +3.89% | ▲ +4.15% | $3.12 (+36.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers